Turbo Cancer Claims

Introduction

"Turbo cancer" is a lay term that emerged in anti-vaccine social media communities in 2022–2023 to describe the alleged phenomenon of unusually aggressive or rapidly progressing cancers developing in COVID-19 mRNA-vaccinated individuals. Proponents claim that mRNA vaccines, through mechanisms including immune suppression, spike protein oncogenic activity, or contaminating SV40 promoter sequences in vaccine plasmid DNA, are causing cancers to appear, progress, or recur at unprecedented speed and severity. The term was widely disseminated by figures including Ryan Cole (a pathologist whose laboratory was subsequently censured by the Medical Board of Washington state), Sucharit Bhakdi, and a network of aligned Substack writers.

Core Claims

• mRNA vaccines cause "turbo cancer" — rapid, aggressive cancers appearing within months of vaccination.
• Spike protein directly promotes tumour cell growth or immune evasion.
• Lipid nanoparticles in vaccines deposit mRNA in the bone marrow, causing haematological malignancies.
• Remnant SV40 promoter sequences in residual plasmid DNA from vaccine manufacturing integrate into human DNA and act as oncogenes.
• VAERS reports show an unprecedented rise in cancer diagnoses following COVID-19 vaccination.
• Oncologists and pathologists are privately documenting turbo cancers but suppressing the findings.

Scientific Assessment

No peer-reviewed epidemiological study has found a vaccine-cancer association. Multiple large population-level studies have examined cancer incidence after COVID-19 vaccination. A 2023 analysis in JAMA Network Open examining over 5 million vaccinated individuals found no increased incidence of 15 types of cancer in the 6 months following vaccination. Studies from Israel (using the Clalit HMO database), Nordic countries (using registry linkage), and the UK''s Clinical Practice Research Datalink have similarly found no signal. The Vaccine Safety Datalink (VSD) in the US, which performs rapid-cycle analysis of dozens of outcomes, has not identified a cancer signal.

The spike protein oncogenic mechanism lacks molecular evidence. Claims that spike protein promotes cancer typically cite two mechanisms: (1) that spike protein suppresses the p53 tumour suppressor pathway, and (2) that it impairs non-homologous end joining (NHEJ) DNA repair. Both claims trace to a single preprint by Jiang and Mei (2021) which was criticised extensively by molecular biologists for methodological errors, was never published in a peer-reviewed journal, and used spike protein concentrations orders of magnitude above physiological vaccine exposure. The paper''s authors themselves noted the limitations of their in vitro model.

SV40 promoter claims misrepresent pharmaceutical manufacturing. The SV40 (Simian Vacuolating Virus 40) promoter sequence is a standard element used in bacterial plasmid construction during vaccine manufacturing. Residual plasmid DNA in final vaccine formulations is present at trace levels, well below FDA-specified limits. The SV40 sequence at issue is a small non-coding regulatory region from bacterial plasmids — not the full SV40 viral genome and not a known human oncogene. The claim that this trace sequence integrates into human chromosomes and causes cancer has no mechanistic evidence; DNA integration from extrachromosomal linear or circular fragments is an extremely inefficient process requiring specific molecular machinery.

VAERS misuse. VAERS (Vaccine Adverse Event Reporting System) is a passive surveillance system designed to generate safety signals for follow-up study. Anyone can submit a report, including for events occurring after vaccination without causal relationship. Post-authorisation COVID-19 vaccination covered hundreds of millions of people in the US; the expected background rate of cancer diagnoses in that population — from pre-existing conditions, delayed diagnoses, and incidental detection — would generate substantial VAERS filings without vaccine causation. VAERS data are explicitly labelled as not supporting causal inference; turbo cancer claims that count VAERS cancer reports as evidence of causation misuse the system.

Ryan Cole and censure. Ryan Cole, a pathologist and prominent turbo cancer advocate, had his licence placed on a reprimand and probation in 2023 by the Medical Board of Washington state following findings that he provided COVID-19 test results that were clinically misleading, prescribed medications without appropriate clinical evaluation, and made unsubstantiated medical claims. His pathology slides presented as evidence of turbo cancer have not been published in peer-reviewed form or validated by independent pathological review.

Real Post-COVID Cancer Dynamics

There is a genuine, documented phenomenon of delayed cancer diagnoses during and after the COVID-19 pandemic. Healthcare disruption in 2020–2021 — reduced cancer screening (colonoscopies, mammograms, PSA tests), delayed primary care visits, overwhelmed oncology departments — caused significant under-detection of early-stage cancers. These cancers are now presenting at more advanced stages, not because they progressed faster, but because they were detected later. This deferred-diagnosis effect is epidemiologically documented and does not require vaccine causation to explain.

COVID-19 infection itself has been associated with post-infection immune dysregulation and possible oncogenic effects in a small number of haematological studies, though this remains an active research area. Importantly, these potential COVID-19-associated cancer risks, if confirmed, would argue in favour of vaccination (which prevents severe COVID-19 infection) rather than against it.

Takeaway

"Turbo cancer" is a social media construct, not a recognised clinical or pathological entity. No peer-reviewed epidemiological study from any country''s vaccine surveillance system has identified an mRNA vaccine-cancer association. The molecular mechanisms proposed — spike protein oncogenesis, SV40 integration, lipid nanoparticle marrow deposition — have no credible supporting evidence in published, peer-reviewed science. Post-pandemic increases in advanced-stage cancer presentations are better explained by the documented deferred-diagnosis effect of healthcare disruption. The "turbo cancer" narrative causes harm by discouraging vaccination and encouraging alternative cancer treatments among newly diagnosed individuals.

Deeper Analysis and Recent Developments

The 2025 South Korean Cohort Study and Its Unraveling

In September 2025 a paper by Kim and colleagues in the journal Biomarker Research reanalysed South Korean National Health Insurance records for more than 8.4 million people followed between 2021 and 2023, reporting higher one-year hazard ratios for several cancers — including thyroid, gastric, colorectal, lung, breast, and prostate — in vaccinated versus unvaccinated groups. Anti-vaccine commentators immediately promoted it as long-awaited proof of turbo cancer. Within weeks, independent epidemiologists identified compounding design flaws, and on 22 October 2025 the journal's editors published a formal Expression of Concern, alerting readers that the article's validity was under investigation.

The flaws are structural. The unvaccinated comparison group was anchored to a single fixed start date, while vaccinated participants' follow-up clocks started on their vaccination date — an "immortal time" bias that systematically excluded early diagnoses from the unvaccinated arm. After matching, the unvaccinated group comprised only about 595,000 people against roughly 2.38 million vaccinated, an imbalance consistent with real differences in how often each group used the healthcare system and therefore how often incidental cancers were caught. The one-year window is far shorter than the years-long latency typical of solid tumours, and the authors ran dozens of cancer-type comparisons without correcting for multiple testing, inflating the odds of chance "significant" findings. Reviewers also noted the reported gap between groups widened for about six months and then ran flat — consistent with a one-time detection difference, not an active carcinogen that should keep diverging over time. As of this writing, the Expression of Concern remains attached and unresolved.

Why "Turbo Cancer" Fails as a Diagnosis

Beyond the absence of population-level evidence, "turbo cancer" fails a more basic test: it is not a diagnosis any pathologist can render. The term appears in no WHO Classification of Tumours volume, no ICD-11 code, and no peer-reviewed oncology taxonomy. Genuine tumour biology does include naturally fast-growing malignancies — certain lymphomas and small-cell lung cancers, for instance — but labelling a case "turbo cancer" typically rests on the patient's vaccination history, not on any distinguishing microscopic feature. A tumour that grew undetected for months, or simply belongs to an aggressive histological subtype, looks identical whether or not the patient was vaccinated. Establishing genuinely accelerated growth requires matched, prospective, blinded comparison — a study turbo-cancer proponents have not produced.

The Mouse Study Behind Many Viral Claims

A frequently recirculated citation is a case report by Belgian researcher Sander Eens and colleagues describing a single laboratory mouse, from a lymphoma-prone strain, that developed lymphoma after a high, intravenously delivered dose of the Pfizer-BioNTech vaccine — a dose and route with no equivalent in human intramuscular vaccination, in an animal already showing signs of illness before injection. Seventy additional mice vaccinated in the same programme developed no cancer. The paper's own authors added an addendum stating plainly that their case report "in no way attempts to demonstrate a causal relationship between the identified lymphoma and the mRNA vaccine," and that online audiences had "largely misinterpreted" the finding. The correction has not stopped the single mouse from being shared as confirmatory human evidence.

The Screening-Delay Evidence in More Detail

The deferred-diagnosis explanation for rising late-stage cancer presentations is well documented independently of vaccination status. A Nordic cancer-registry analysis across Denmark, Finland, Iceland, Norway, and Sweden found overall cancer diagnoses fell by as much as 21.7% in Sweden in the second quarter of 2020 alone, with reduced early-stage detection of breast, prostate, and colorectal cancers persisting into 2021 as screening programmes were disrupted. In the United States, a nationwide registry analysis covering roughly 70% of diagnosed cancers found monthly diagnoses roughly halved in April 2020, early-stage diagnoses down nearly 20% for the pandemic's first year, and patients across nearly all cancer types correspondingly more likely to present at stage 4. Oncologists have since described some of the highest volumes of advanced-stage disease seen in over a decade during 2022–2023 — a timeline that tracks missed screening far better than any hypothesised vaccine mechanism.

Continuing Consequences for Promoters

Professional consequences for turbo-cancer's most visible promoter have continued to unfold. In May 2025 the Idaho Board of Medicine finalised a reciprocal discipline agreement requiring Ryan Cole to comply with Washington's restrictions on his license, following Washington's January 2024 order restricting him for five years from practising primary care or prescribing medication over COVID-19 disinformation and improper telehealth ivermectin prescribing. Cole denies the underlying allegations and has appealed; no independent pathology body has validated the slide-based claims he has presented publicly as evidence of turbo cancer.